tert-butyl 4-(4-(5,5-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenoxy)piperidine-1-carboxylate | 1359853-59-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(4-(5,5-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenoxy)piperidine-1-carboxylate
• CAS: 1359853-59-0
• 化学式: C₂₂H₃₁N₃O₄
• 分子量: 401.506
• InChiKey: PJYBFYJVFXAKFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.72
• 重原子数：
  29.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  80.23
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(4-(5,5-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenoxy)piperidine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  4-Phenoxypiperidine pyridazin-3-one histamine H3 receptor inverse agonists demonstrating potent and robust wake promoting activity

  摘要：

  Structure-activity relationships for a series of phenoxypiperidine pyridazin-3-one H3R antagonists/inverse agonists are disclosed. The search for compounds with improved hERG and DAT selectivity without the formation of in vivo active metabolites identified 6-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]- 4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one 17b. Compound 17b met discovery flow criteria, demonstrated potent H3R functional antagonism in vivo in the rat dipsogenia model and potent wake activity in the rat EEG/EMG model at doses as low as 0.1 mg/kg ip. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.026
• 作为产物：
  描述：

  在 肼 作用下， 以 异丙醇 为溶剂， 生成 tert-butyl 4-(4-(5,5-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenoxy)piperidine-1-carboxylate
  参考文献：
  名称：

  4-Phenoxypiperidine pyridazin-3-one histamine H3 receptor inverse agonists demonstrating potent and robust wake promoting activity

  摘要：

  Structure-activity relationships for a series of phenoxypiperidine pyridazin-3-one H3R antagonists/inverse agonists are disclosed. The search for compounds with improved hERG and DAT selectivity without the formation of in vivo active metabolites identified 6-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]- 4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one 17b. Compound 17b met discovery flow criteria, demonstrated potent H3R functional antagonism in vivo in the rat dipsogenia model and potent wake activity in the rat EEG/EMG model at doses as low as 0.1 mg/kg ip. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.026

文献信息

• Direct α‐Tertiary Alkylations of Ketones in a Combined Copper–Organocatalyst System
  作者：Ayako Kurose、Yuto Ishida、Goki Hirata、Takashi Nishikata

  DOI：10.1002/anie.202016051

  日期：2021.5.3

  Herein, we report an efficient method for the tertiary alkylation of a ketone by using an α‐bromocarbonyl compound as the tertiary alkyl source in a combined Cu‐organocatalyst system. This dual catalyst system enables the addition of a tertiary alkyl radical to an enamine. Mechanistic studies revealed that the catalytically generated enamine is a key intermediate in the catalytic cycle. The developed

  在本文中，我们报告了一种有效的方法，通过在复合有机铜催化剂体系中使用α-溴羰基化合物作为叔烷基源，可以使酮进行叔烷基化。这种双重催化剂体系能够将叔烷基加成到烯胺上。机理研究表明，催化生成的烯胺是催化循环中的关键中间体。所开发的方法可用于合成取代的1,4-二羰基化合物，这些化合物包含带有各种烷基链的季碳。